0.2966
price up icon2.04%   0.00263
 
loading
Precedente Chiudi:
$0.294
Aprire:
$0.294
Volume 24 ore:
22,243
Relative Volume:
0.11
Capitalizzazione di mercato:
$9.71M
Reddito:
-
Utile/perdita netta:
$-117.67M
Rapporto P/E:
-0.096
EPS:
-3.09
Flusso di cassa netto:
$-101.06M
1 W Prestazione:
+11.52%
1M Prestazione:
-1.64%
6M Prestazione:
-38.03%
1 anno Prestazione:
-84.77%
Intervallo 1D:
Value
$0.275
$0.30
Intervallo di 1 settimana:
Value
$0.2601
$0.3113
Portata 52W:
Value
$0.2195
$3.67

Athira Pharma Inc Stock (ATHA) Company Profile

Name
Nome
Athira Pharma Inc
Name
Telefono
(425) 620-8501
Name
Indirizzo
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Name
Dipendente
26
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-07
Name
Ultimi documenti SEC
Name
ATHA's Discussions on Twitter

Confronta ATHA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ATHA
Athira Pharma Inc
0.30 9.71M 0 -117.67M -101.06M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.41 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.57 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
633.00 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.44 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
247.69 24.70B 3.81B -644.79M -669.77M -6.24

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-09-19 Downgrade Mizuho Outperform → Neutral
2024-09-04 Downgrade BTIG Research Buy → Neutral
2024-09-04 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2024-09-04 Downgrade Rodman & Renshaw Buy → Neutral
2024-08-19 Iniziato Rodman & Renshaw Buy
2022-10-17 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2022-07-07 Iniziato Mizuho Buy
2022-06-23 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2022-06-23 Downgrade Jefferies Buy → Hold
2022-06-23 Downgrade Stifel Buy → Hold
2022-05-10 Iniziato BTIG Research Buy
2022-04-21 Iniziato Berenberg Buy
2021-12-15 Iniziato Goldman Neutral
2020-10-13 Iniziato Goldman Buy
2020-10-13 Iniziato JMP Securities Mkt Outperform
2020-10-13 Iniziato Jefferies Buy
2020-10-13 Iniziato Stifel Buy
Mostra tutto

Athira Pharma Inc Borsa (ATHA) Ultime notizie

pulisher
Apr 17, 2025

Athira Pharma shifts to Nasdaq Capital Market amid compliance bid By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 16, 2025

Athira Pharma shifts to Nasdaq Capital Market amid compliance bid - Investing.com Australia

Apr 16, 2025
pulisher
Apr 07, 2025

Athira Pharma stock plunges to 52-week low of $0.25 - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Athira Pharma stock plunges to 52-week low of $0.25 By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 04, 2025

SEC Form PRE 14A filed by Athira Pharma Inc. - Quantisnow

Apr 04, 2025
pulisher
Mar 28, 2025

Athira Pharma stock hits 52-week low at $0.3 amid steep decline - Investing.com India

Mar 28, 2025
pulisher
Mar 27, 2025

Athira Pharma stock hits 52-week low at $0.3 amid steep decline By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 13, 2025

What is ATHA’s price-to-sales ratio telling us about the company’s value? - US Post News

Mar 13, 2025
pulisher
Mar 11, 2025

Athira Pharma: Hold Rating Amid Strategic Uncertainty and Resource Challenges - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Athira Pharma stock hits 52-week low at $0.33 amid steep decline - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Athira Pharma stock hits 52-week low at $0.33 amid steep decline By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 07, 2025

Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga

Mar 07, 2025
pulisher
Mar 03, 2025

Athira Pharma’s Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating Maintained - TipRanks

Mar 03, 2025
pulisher
Mar 02, 2025

Athira Pharma’s 2024 Financial Results and Pipeline Progress - MSN

Mar 02, 2025
pulisher
Feb 27, 2025

Athira Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Athira Pharma, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 26, 2025

Athira Pharma stock hits 52-week low at $0.41 amid steep decline - Investing.com Australia

Feb 26, 2025
pulisher
Feb 25, 2025

Athira Pharma stock hits 52-week low at $0.41 amid steep decline By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 24, 2025

Athira Pharma Inc expected to post a loss of 44 cents a shareEarnings Preview - TradingView

Feb 24, 2025
pulisher
Feb 24, 2025

Can This Former Amgen VP Transform Terns Pharmaceuticals as New CFO? - Stock Titan

Feb 24, 2025
pulisher
Feb 21, 2025

ATHA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Molecular Partners (NASDAQ:MOLN) versus Athira Pharma (NASDAQ:ATHA) Head to Head Review - Defense World

Feb 21, 2025
pulisher
Feb 13, 2025

Athira Pharma (ATHA) Expected to Announce Earnings on Thursday - Defense World

Feb 13, 2025
pulisher
Jan 30, 2025

Alterity stock jumps on data for lead drug (ATHA:NASDAQ) - Seeking Alpha

Jan 30, 2025
pulisher
Jan 28, 2025

Can Athira Pharma (NASDAQ:ATHA) Afford To Invest In Growth? - Yahoo Finance

Jan 28, 2025
pulisher
Jan 21, 2025

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct - MSN

Jan 21, 2025
pulisher
Jan 17, 2025

Insider Buyers Lose Additional US$78k As Athira Pharma Dips To US$21m - Simply Wall St

Jan 17, 2025
pulisher
Jan 14, 2025

Keeping Fraud Out of Research: Government Grant Whistleblower Awarded Over $200,000 - The National Law Review

Jan 14, 2025
pulisher
Jan 14, 2025

Will Athira Pharma See A Boost From LIFT-AD Trial Results In Alzheimer's Research? - RTTNews

Jan 14, 2025
pulisher
Jan 10, 2025

Alzheimer’s Drugmaker Athira Shells Out $4 Million In DOJ Settlement - Being Patient

Jan 10, 2025
pulisher
Jan 08, 2025

Athira to pay $4M to resolve research misconduct allegations - BioWorld Online

Jan 08, 2025
pulisher
Jan 08, 2025

ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024 - MSN

Jan 08, 2025
pulisher
Jan 08, 2025

Whistleblower Receives $200K After Alleging Scientific Research Misconduct - Whistleblower Network News

Jan 08, 2025
pulisher
Jan 08, 2025

Bothell's Athira Pharma to pay $4M to settle falsified research claims - The Business Journals

Jan 08, 2025
pulisher
Jan 07, 2025

Biotech company agrees to pay $4 million to settle data falsification allegations - Retraction Watch

Jan 07, 2025
pulisher
Jan 06, 2025

Athira Inks $4M FCA Deal Over Ex-CEO's Research Fraud - Law360

Jan 06, 2025
pulisher
Jan 06, 2025

Athira Pharma Inc. Agrees to Pay $4M to Settle False Claims Act Allegations Related to Scientific Research - U.S. Politics Today

Jan 06, 2025
pulisher
Jan 06, 2025

Athira Pharma to Pay $4 Million Over Alleged Research Misconduct - Marketscreener.com

Jan 06, 2025
pulisher
Jan 06, 2025

Bothell pharma company to pay $4 million over falsified research claims - MSN

Jan 06, 2025
pulisher
Jan 06, 2025

Athira Pharma Settles Claims of NIH Research Grant Misconduct - Bloomberg Law

Jan 06, 2025
pulisher
Jan 04, 2025

Athira Pharma CEO sells shares worth $14,107 By Investing.com - Investing.com South Africa

Jan 04, 2025

Athira Pharma Inc Azioni (ATHA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Athira Pharma Inc Azioni (ATHA) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
San Martin Javier
CHIEF MEDICAL OFFICER
Jan 02 '25
Sale
0.56
10,826
6,083
35,841
Litton Mark James
President and CEO
Dec 31 '24
Option Exercise
0.00
108,333
0
267,698
Litton Mark James
President and CEO
Jan 02 '25
Sale
0.56
25,107
14,108
242,591
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Dec 31 '24
Option Exercise
0.00
36,667
0
139,271
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Jan 02 '25
Sale
0.56
8,510
4,782
130,761
Renninger Robert
VP of Finance
Dec 31 '24
Option Exercise
0.00
12,359
0
92,605
Renninger Robert
VP of Finance
Jan 02 '25
Sale
0.56
2,881
1,619
89,724
Worthington Mark
General Counsel and CCO
Dec 31 '24
Option Exercise
0.00
36,667
0
92,245
Worthington Mark
General Counsel and CCO
Jan 02 '25
Sale
0.56
8,510
4,782
83,735
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
Capitalizzazione:     |  Volume (24 ore):